Department of Pharmacy, The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Invest New Drugs. 2022 Oct;40(5):1153-1159. doi: 10.1007/s10637-022-01288-6. Epub 2022 Jul 22.
Knowledge of dasatinib-induced nephrotic syndrome is largely based on case reports. The clinical features of dasatinib-induced nephrotic syndrome are unknown. We collected case reports of 25 patients with nephrotic syndrome and analyzed their clinical characteristics. Overall, the onset of nephrotic syndrome ranged from 10 days to 5 years after dasatinib administration. Nine patients (36.0%) had clinical symptoms, mainly periorbital edema and lower-extremity edema. Serum albumin ranged from 1.2 g/dL to 3.7 g/dL in 10 patients (38.5%). The 24-h urine protein values ranged from 3.54 g/day to 118 g/day. Kidney biopsy of 13 patients (52.0%) mainly showed focal foot process effacement, mesangial hyperplasia, endothelial cell damage and focal segmental glomerulosclerosis. Proteinuria resolved or recovered after dasatinib discontinuation or dose reduction or switching to other tyrosine kinase inhibitors (TKIs).
达沙替尼诱导的肾病综合征的知识主要基于病例报告。达沙替尼诱导的肾病综合征的临床特征尚不清楚。我们收集了 25 例肾病综合征患者的病例报告，并对其临床特征进行了分析。总体而言，肾病综合征在达沙替尼治疗后 10 天至 5 年内发病。9 例患者（36.0%）有临床症状，主要为眶周水肿和下肢水肿。10 例患者（38.5%）血清白蛋白为 1.2g/dL 至 3.7g/dL。24 小时尿蛋白值为 3.54g/天至 118g/天。13 例患者（52.0%）的肾活检主要表现为局灶性足细胞足突消失、系膜细胞增生、内皮细胞损伤和局灶节段性肾小球硬化。达沙替尼停药或减量或换用其他酪氨酸激酶抑制剂（TKI）后蛋白尿缓解或恢复。
